1. Home
  2. KYMR
  3. KYMR News

Latest Kymera Therapeutics Inc. (KYMR) News on November 4, 2025

KYMR

MT Newswires

5 days ago

Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases
KYMR

Simply Wall St.

6 days ago

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA
KYMR

Simply Wall St.

6 days ago

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
KYMR

GlobeNewswire

7 days ago

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

KYMR

MT Newswires

14 days ago

Mizuho Initiates Kymera Therapeutics at Outperform With $81 Price Target

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
KYMR

Zacks

a month ago

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
KYMR

Insider Monkey

4 months ago

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

KYMR

Investing.com

4 months ago

Kymera’s partnerships with Sanofi and Gilead drive value

KYMR

MT Newswires

4 months ago

Oppenheimer Adjusts Kymera Therapeutics Price Target to $53 From $56, Maintains Outperform Rating

KYMR

MT Newswires

4 months ago

Kymera Therapeutics Prices $250.8 Million Public Offering

Kymera Therapeutics Announces Pricing of $250 Million Public Offering
KYMR

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera weakness a buying opportunity, says Stifel
KYMR

TipRanks

4 months ago

Kymera weakness a buying opportunity, says Stifel

Morning Movers: General Mills dips following fourth quarter report
KYMR

TipRanks

4 months ago

Morning Movers: General Mills dips following fourth quarter report

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
KYMR

Zacks

4 months ago

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

KYMR

MT Newswires

4 months ago

HC Wainwright Adjusts Price Target on Kymera Therapeutics to $60 From $54, Maintains Buy Rating

KYMR

MT Newswires

4 months ago

Kymera Therapeutics Commences $250 Million Public Offering

Kymera Therapeutics Announces Proposed Public Offering
KYMR

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Proposed Public Offering

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal
KYMR

Simply Wall St.

4 months ago

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
KYMR

BioPharma Dive

4 months ago

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

KYMR

MT Newswires

4 months ago

Kymera Announces Sanofi to Advance KT-485 Into Clinical Testing

KYMR

MT Newswires

4 months ago

Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
KYMR

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
KYMR

Business Wire

4 months ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Kymera Therapeutics Stock Earns 92 RS Rating
KYMR

Investor's Business Daily

5 months ago

Kymera Therapeutics Stock Earns 92 RS Rating

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
KYMR

Barrons.com

5 months ago

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial

KYMR

MT Newswires

5 months ago

Kymera Therapeutics Insider Sold Shares Worth $1,470,000, According to a Recent SEC Filing

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
KYMR

Zacks

5 months ago

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug

KYMR

MT Newswires

5 months ago

Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says

KYMR

MT Newswires

5 months ago

Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating

KYMR

MT Newswires

5 months ago

B. Riley Upgrades Kymera Therapeutics to Buy From Neutral, Adjusts Price Target to $60 From $38

KYMR

MT Newswires

5 months ago

Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49

Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
KYMR

Insider Monkey

5 months ago

Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday

KYMR

MT Newswires

5 months ago

BofA Securities Upgrades Kymera Therapeutics to Buy From Neutral, $51 Price Target; Shares Rise

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
KYMR

Benzinga

5 months ago

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

KYMR

MT Newswires

5 months ago

Kymera Therapeutics Says KT-621 Well Tolerated in Phase 1 Trial, Showing Potential to Treat Th2 Diseases

Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
KYMR

Barrons.com

5 months ago

Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Kymera Therapeutics to Participate in Upcoming June Investor Conferences
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

KYMR

MT Newswires

6 months ago

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating

KYMR

MT Newswires

6 months ago

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating

Kymera Therapeutics First Quarter 2025 Earnings: Beats Expectations
KYMR

Simply Wall St.

6 months ago

Kymera Therapeutics First Quarter 2025 Earnings: Beats Expectations

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ...
KYMR

GuruFocus.com

6 months ago

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
KYMR

Zacks

6 months ago

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
KYMR

Zacks

6 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

KYMR

MT Newswires

6 months ago

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings
KYMR

GuruFocus.com

6 months ago

What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Why Kymera Therapeutics Stock Crushed it This Week
KYMR

Motley Fool

6 months ago

Why Kymera Therapeutics Stock Crushed it This Week

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
KYMR

Zacks

7 months ago

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
KYMR

GlobeNewswire

7 months ago

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

KYMR

MT Newswires

8 months ago

Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook
KYMR

Simply Wall St.

8 months ago

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
KYMR

Simply Wall St.

8 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
KYMR

Zacks

8 months ago

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate
KYMR

Simply Wall St.

8 months ago

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...
KYMR

GuruFocus.com

8 months ago

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

KYMR

MT Newswires

8 months ago

Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
KYMR

Zacks

8 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

8 months ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings
KYMR

GuruFocus.com

8 months ago

What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings

Kymera Therapeutics to Participate in Upcoming March Investor Conferences
KYMR

GlobeNewswire

8 months ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
KYMR

GlobeNewswire

8 months ago

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

NAYA Biosciences Announces Nomination of New Board Members
KYMR

GlobeNewswire

9 months ago

NAYA Biosciences Announces Nomination of New Board Members

Kymera Therapeutics to Participate in Upcoming February Investor Conferences
KYMR

GlobeNewswire

9 months ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Kymera Provides Pipeline Objectives for 2025, Stock Gains
KYMR

Zacks

10 months ago

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
KYMR

Zacks

10 months ago

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments
KYMR

GuruFocus.com

10 months ago

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
KYMR

TipRanks

10 months ago

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal

KYMR

MT Newswires

a year ago

BMO Capital Initiates Kymera Therapeutics at Market Perform With $55 Price Target

KYMR

MT Newswires

a year ago

Kymera Therapeutics Shares Rise After Upgrade From Wells Fargo

KYMR

MT Newswires

a year ago

Wells Fargo Upgrades Kymera Therapeutics to Overweight, Price Target is $57

Kymera Therapeutics to Participate in Upcoming December Investor Conferences
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Kymera Therapeutics to Participate in Upcoming November Investor Conferences
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

KYMR

MT Newswires

a year ago

UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
KYMR

Simply Wall St.

a year ago

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
KYMR

Simply Wall St.

a year ago

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
KYMR

Zacks

a year ago

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

KYMR

MT Newswires

a year ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $41 From $36, Maintains Neutral Rating

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
KYMR

GuruFocus.com

a year ago

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
KYMR

The Wall Street Journal

a year ago

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

KYMR

MT Newswires

a year ago

Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating

KYMR

MT Newswires

a year ago

Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
KYMR

Zacks

a year ago

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings
KYMR

GuruFocus.com

a year ago

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
KYMR

Zacks

a year ago

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
KYMR

Zacks

a year ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
KYMR

GlobeNewswire

a year ago

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
KYMR

Zacks

a year ago

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

KYMR

MT Newswires

a year ago

Kymera Therapeutics Says US FDA Clears Investigational New Drug Application for KT-621

Share on Social Networks: